Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis
Novartis
Takeda
University of Chicago
University of Nebraska
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
Gamida Cell ltd
BeOne Medicines
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute
Mayo Clinic
University of Rochester
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
University of Iowa
Medical College of Wisconsin
University of Colorado, Denver
Children's Hospital of Philadelphia
University of Rochester
M.D. Anderson Cancer Center
Chang Gung University
M.D. Anderson Cancer Center
Brown University
Acerta Pharma BV
Pfizer
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Thomas Jefferson University
University of California, San Diego
Acerta Pharma BV
H. Lee Moffitt Cancer Center and Research Institute
Thomas Jefferson University
Pfizer
Astellas Pharma Inc
Case Comprehensive Cancer Center
Mayo Clinic
Pfizer
City of Hope Medical Center
Case Comprehensive Cancer Center
Novartis
Hoffmann-La Roche
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Thomas Jefferson University
Takeda
NHS Blood and Transplant
Therapeutic Advances in Childhood Leukemia Consortium
Medical College of Wisconsin